or Try an Advanced Search...

    Technical Analysis for INM - InMed Pharmaceuticals Inc.

    Grade Last Price % Change Price Change
    F 0.24 -4.72% -0.01
    INM closed down 16.83 percent on Thursday, April 25, 2024, on 1.43 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 13
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical INM trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish -4.72%
    NR7 Range Contraction -4.72%
    Narrow Range Bar Range Contraction -4.72%
    Lower Bollinger Band Walk Weakness -4.72%
    New 52 Week Low Weakness -4.72%
    Wide Bands Range Expansion -4.72%
    Below Lower BB Weakness -4.72%
    Gapped Down Weakness -4.72%
    Lower Bollinger Band Touch Weakness -4.72%
    Oversold Stochastic Weakness -4.72%
    Older End-of-Day Signals for INM ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Lower Bollinger Band 33 minutes ago
    2x Volume Pace 33 minutes ago
    1.5x Volume Pace 33 minutes ago
    3x Volume Pace 33 minutes ago
    Down 5% 33 minutes ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    INM Chart by TradingView
    Basic chart:

    Profile

    InMed Pharmaceuticals Inc. Description

    InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Disease Rare Diseases Cannabis Pharmacology Dermatology Stage Pharmaceutical Glaucoma Toxicology Genodermatoses Treatment Of Glaucoma Cannabinoid Epidermolysis Bullosa Ocular Disease

    Is INM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 18 InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
    Apr 16 InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
    Apr 4 InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
    Mar 20 InMed Pharmaceuticals gets 180-Day extension to regain compliance with Nasdaq
    Mar 20 InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
    Feb 23 InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
    Feb 22 Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
    Feb 13 InMed Pharmaceuticals GAAP EPS of -$0.19, revenue of $1.24M beats by $0.12M
    Feb 13 InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
    Feb 9 InMed Pharmaceuticals announces appointment of Netta Jagpal as CFO
    See more INM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.08
    52 Week Low 0.25
    Average Volume 436,738
    200-Day Moving Average 0.55
    50-Day Moving Average 0.35
    20-Day Moving Average 0.32
    10-Day Moving Average 0.30
    Average True Range 0.04
    RSI (14) 32.89
    ADX 33.1
    +DI 22.50
    -DI 16.56
    Chandelier Exit (Long, 3 ATRs) 0.33
    Chandelier Exit (Short, 3 ATRs) 0.37
    Upper Bollinger Bands 0.39
    Lower Bollinger Band 0.26
    Percent B (%b) -0.03
    BandWidth 41.08
    MACD Line -0.02
    MACD Signal Line -0.02
    MACD Histogram -0.0056
    Fundamentals Value
    Market Cap 1.66 Million
    Num Shares 6.6 Million
    EPS 0.05
    Price-to-Earnings (P/E) Ratio 5.04
    Price-to-Sales 0.48
    Price-to-Book 0.23
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.28
    Resistance 3 (R3) 0.28 0.27 0.27
    Resistance 2 (R2) 0.27 0.27 0.27 0.27
    Resistance 1 (R1) 0.26 0.26 0.26 0.26 0.27
    Pivot Point 0.26 0.26 0.25 0.25 0.26
    Support 1 (S1) 0.25 0.25 0.24 0.24 0.24
    Support 2 (S2) 0.24 0.25 0.24 0.23
    Support 3 (S3) 0.23 0.24 0.23
    Support 4 (S4) 0.23